With strong 1-year returns and upside potential, DBV Technologies S.A. (NASDAQ:DBVT) secures a spot on our list of the 12 ...

DBV Technologies stock rallied on Wednesday following analyst price target increases after the company’s latest clinical ...

DBV Technologies SA said its experimental skin patch helped young children with a peanut allergy in a crucial study.

Châtillon, France, December 16, 2025DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of ...

DBV Technologies (DBVT) climbed ~41% in the premarket on Wednesday after the French biotech announced that a Phase 3 trial ...

Shares in the company rose more than 35% on the strength of the data, which could put DBV on track to bring the immunotherapy ...

DBV Technologies recently reported that its pivotal Phase 3 VITESSE trial of the Viaskin Peanut patch in children aged 4–7 met its primary endpoint with statistically significant desensitization and a ...

Investing.com -- DBV Technologies (NASDAQ:DBVT) stock soared 65.2% in after-hours trading Tuesday following the announcement of positive topline results from its Phase 3 VITESSE trial for the VIASKIN ...

French biopharma DBV Technologies has rewarded the faith of long-term investors with compelling pivotal Phase III results on ...

DBV Technologies reports positive Phase 3 data for its VIASKIN Peanut patch in children, supporting a planned U.S. BLA filing ...

DBV Technologies' lead asset, Viaskin Peanut, is being evaluated in two Phase 3 trials targeting peanut allergies. See why ...

DBV Technologies patch treatment for children allergic to peanuts met its primary endpoint in a Phase 3 trial. The biopharmaceutical company said Tuesday 46.6% of children who used the patch, named ...